Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report), Evolent Health (EVH – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report).
Biogen (BIIB)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen yesterday and set a price target of $317.00. The company’s shares closed last Wednesday at $201.99, close to its 52-week low of $189.44.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $283.52 average price target, a 42.5% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $308.00 price target.
See the top stocks recommended by analysts >>
Evolent Health (EVH)
In a report released yesterday, Sean Dodge from RBC Capital maintained a Buy rating on Evolent Health, with a price target of $42.00. The company’s shares closed last Wednesday at $29.26.
According to TipRanks.com, Dodge is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolent Health with a $45.90 average price target, which is a 52.7% upside from current levels. In a report issued on April 22, Citi also initiated coverage with a Buy rating on the stock with a $40.00 price target.
BioMarin Pharmaceutical (BMRN)
RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical yesterday and set a price target of $100.00. The company’s shares closed last Wednesday at $91.20.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $111.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
